Serotiny
Serotiny, founded by brothers Justin and Colin Farlow, is a San Francisco-based biotechnology company specializing in next-generation cell and gene therapies to treat a broad spectrum of diseases including cancers such as multiple myeloma, prostate cancer, and lung cancer. The company has developed proprietary software and lab techniques that enable the design and testing of thousands of therapeutic genes simultaneously, accelerating discovery and innovation in cell therapies like CAR-T. Serotiny's technology allows rapid identification of promising new gene designs, significantly improving the pace and creativity of therapy development. The company was acquired by Johnson & Johnson in 2024 and collaborates within JLABS, Johnson & Johnson's startup incubator, to advance its mission of transforming cancer treatment outcomes at scale.
Serotiny
Serotiny, founded by brothers Justin and Colin Farlow, is a San Francisco-based biotechnology company specializing in next-generation cell and gene therapies to treat a broad spectrum of diseases including cancers such as multiple myeloma, prostate cancer, and lung cancer. The company has developed proprietary software and lab techniques that enable the design and testing of thousands of therapeutic genes simultaneously, accelerating discovery and innovation in cell therapies like CAR-T. Serotiny's technology allows rapid identification of promising new gene designs, significantly improving the pace and creativity of therapy development. The company was acquired by Johnson & Johnson in 2024 and collaborates within JLABS, Johnson & Johnson's startup incubator, to advance its mission of transforming cancer treatment outcomes at scale.